

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Nordion (Canada) Inc.</p> <p>2. 447 March Road Ottawa, Ontario, Canada K2K 1X8</p>	<p>In accordance with the current NRC policy,</p> <p>3. License number 54-28275-02MD is administratively amended in its entirety to read as follows:</p> <p>4. Expiration date March 31, 2025</p> <p>5. Docket No. 03030793 Reference No.</p>
--	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Iodine 123</p> <p>B. Iodine 125</p> <p>C. Iodine 131</p> <p>D. Yttrium-90</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Glass microspheres (Nordion (Canada), Inc., Model TheraSphere)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. Not Applicable</p> <p>B. Not Applicable</p> <p>C. Not Applicable</p> <p>D. Not to exceed 540 millicuries per administration set</p>
--	--	---

9. Authorized use:
- A. through C. Pursuant to 10 CFR 32.72, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed pursuant to 10 CFR Part 35.100, 35.200, 35.300 or under equivalent licenses of any Agreement State.
- D. Pursuant to 10 CFR 32.74, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed pursuant to 10 CFR 35.1000, or under equivalent licenses of any Agreement State.

CONDITIONS

10. The licensee may distribute material from 447 March Road, Ottawa, Ontario, Canada and 4004 Wesbrook Mall, Vancouver, British Columbia, Canada.
11. This license does not authorize possession or use of licensed material.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
54-28275-02MDDocket or Reference Number
03030793

Amendment No. 11

12. By April 1, 2016, provide evidence that you are registered or licensed with the U. S. Food and Drug Administration (FDA) as a drug manufacturer as required by 10 CFR 32.72(a)(2). Alternatively, you may submit evidence from the FDA to support relief from this requirement.
13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.


A. Application dated September 23, 2014 [ML14279A523]

B. Letter dated February 25, 2015 [ML15071A409]

C. Letter dated March 18, 2015 [ML15086A153]

D. Letter dated March 30, 2015 [ML15090A161]

E. Letter dated May 19, 2015 [ML15159A919]



For the U.S. Nuclear Regulatory Commission

Original signed by Dennis R. LawyerDate June 17, 2015

By _____

Dennis R. Lawyer
Commercial, Industrial, R&D and Academic Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406